A meningeomák molekuláris patológiája

Translated title of the contribution: Molecular pathology of meningiomas

Murnyák Balázs, Csonka Tamás, Hortobágyi Tibor

Research output: Contribution to journalArticle

6 Citations (Scopus)


Meningiomas represent nearly one-third of all adult primary brain tumours. According to their clinical and histologic appearance, they can be divided into WHO grades 1-111. Almost 90% of meningiomas are benign, showing favourable response to conventional therapies, however, patients diagnosed with grade 2 and 3 tumours may have a poor prognosis. In addition, high frequency of tumour recurrence renders treatments more challenging even in benign meningiomas. Molecular-pathological profiling of meningiomas could lead to development of more effective therapies. Although the cytogenetic background of these tumours are already wellcharacterised, the majority of related genes and mutations is still unknown. Recently, high-throughput techniques enabled better characterisation of mechanisms involved in meningioma development, progression and recurrence. Furthermore, epigenetic dysregulation could offer new opportunities for both diagnosis and treatment of meningiomas. We provide a comprehensive overview of cytogenetic and molecular genetic defects as well as epigenetic alterations in meningiomas. Many of these may serve as biomarker or therapeutic target in the near future.

Translated title of the contributionMolecular pathology of meningiomas
Original languageHungarian
Pages (from-to)292-300
Number of pages9
JournalIdeggyogyaszati szemle
Issue number9-10
Publication statusPublished - Sep 30 2015

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Molecular pathology of meningiomas'. Together they form a unique fingerprint.

  • Cite this